Ubels John L, Clousing Daniel P, Van Haitsma Timothy A, Hong Bor-Shyue, Stauffer Peggy, Asgharian Bahram, Meadows David
Department of Biology, Calvin College, Grand Rapids, MI 49546, USA.
Curr Eye Res. 2004 Jun;28(6):437-44. doi: 10.1080/02713680490503787.
Pre-clinical studies of a new artificial tear product (Systane Lubricating Eye Drops Alcon Laboratories, Inc., Fort Worth, TX) containing the novel gelling agent hydroxypropyl-guar (HP-guar) and two demulcents, polyethylene glycol 400 (PEG) and propylene glycol (PG) were conducted to determine the ability of the product to protect ocular surface epithelial cells from desiccation in vivo and in vitro, and to promote recovery of the damaged corneal epithelial barrier in vivo. Other leading artificial tear products were also evaluated as comparators to determine the relative effectiveness of different polymer systems.
Damage due to desiccation was assessed by measuring corneal uptake of methylene blue compared to untreated corneas. Corneas of anesthetized rabbits were treated with the new artificial tear product and subjected to desiccation by holding the eyelids open for 2 hours with a speculum. Control eyes were subjected to desiccation without application of a tear formulation. To measure recovery of the corneal epithelium from damage, corneas of anethesthetized rabbits were exposed to 0.01% benzalkonium chloride (BAC) for 5 minutes to increase epithelial permeability. The corneas were exposed to the new artificial tear for 1.5 hours followed by measurement of uptake of 5,6 carboxyfluorescein (CF). In the desiccation and CF uptake experiments, the new tear product was also compared to a tear product formulation without HP-guar and to a commercially available artificial tear containing carboxymethyl cellulose (CMC) and Purite. In a third set of experiments, immortalized human corneal epithelial cells and Chang conjunctival cells in culture were exposed to the PEG/PG/HP-guar tear product, the control formulation without HP-guar, a tear formulation preserved with BAC, or the artificial tear containing CMC/Purite for 15min. The tear formulation was removed and the cells were exposed to desiccating conditions in a laboratory safety hood for 10 or 30min. Cell viability was determined using the MTT assay.
The in vivo desiccation model, showed that the new tear product, Systane, offered complete protection of the cornea from desiccation (methylene blue uptake not different than naïve control). Following exposure to 0.01% BAC, the new artificial tear product also provided an environment in which the corneal epithelium recovered completely from damage (CF uptake not different than normal, untreated cornea). This level of protection was not observed when corneas were treated with other formulations. Results from the in vitro desiccation procedure indicated that viability of corneal epithelial and Chang cells treated with the PEG/PG/HP-guar product was significantly greater than viability of cells treated with the tear product without HP-guar or the tear products containing BAC or CMC/Purite.
The tear product containing HP-guar, PEG 400 and propylene glycol satisfies several pre-clinical criteria for an appropriate artificial tear formulation. It gives long-term desiccation protection of the intact cornea and also epithelial cells in culture and has no apparent deleterious affects on cells. It also provides conditions in which a damaged corneal epithelium can recover normal barrier function. The combination of ingredients in the formulation appears to provide an effective mucomimetic artificial tear product. These pre-clinical data suggest that the product will be effective in providing superior relief for the dry eye sufferer.
对一种新型人工泪液产品(思然润滑滴眼液,爱尔康实验室公司,沃思堡,德克萨斯州)进行临床前研究,该产品含有新型胶凝剂羟丙基瓜尔胶(HP-瓜尔胶)以及两种缓和剂,聚乙二醇400(PEG)和丙二醇(PG),以确定该产品在体内和体外保护眼表上皮细胞免受干燥影响的能力,以及在体内促进受损角膜上皮屏障恢复的能力。还评估了其他领先的人工泪液产品作为对照,以确定不同聚合物系统的相对有效性。
通过测量与未处理角膜相比的角膜对亚甲蓝的摄取来评估干燥引起的损伤。用新的人工泪液产品处理麻醉兔的角膜,并用窥器撑开眼睑2小时使其干燥。对照眼在不应用泪液制剂的情况下进行干燥处理。为了测量角膜上皮从损伤中的恢复情况,将麻醉兔的角膜暴露于0.01%苯扎氯铵(BAC)5分钟以增加上皮通透性。角膜暴露于新的人工泪液1.5小时,然后测量5,6-羧基荧光素(CF)的摄取。在干燥和CF摄取实验中,新的泪液产品还与不含HP-瓜尔胶的泪液产品制剂以及含有羧甲基纤维素(CMC)和Purite的市售人工泪液进行了比较。在第三组实验中,将永生化人角膜上皮细胞和培养的张氏结膜细胞暴露于PEG/PG/HP-瓜尔胶泪液产品、不含HP-瓜尔胶的对照制剂、用BAC保存的泪液制剂或含有CMC/Purite的人工泪液中15分钟。去除泪液制剂,将细胞置于实验室安全柜中的干燥条件下10或30分钟。使用MTT法测定细胞活力。
体内干燥模型表明,新的泪液产品思然能为角膜提供完全的干燥保护(亚甲蓝摄取与未处理的对照无差异)。暴露于0.01%BAC后,新的人工泪液产品还提供了一种环境,使角膜上皮从损伤中完全恢复(CF摄取与正常未处理角膜无差异)。当用其他制剂处理角膜时,未观察到这种保护水平。体外干燥程序的结果表明,用PEG/PG/HP-瓜尔胶产品处理的角膜上皮细胞和张氏细胞的活力明显高于用不含HP-瓜尔胶的泪液产品或含有BAC或CMC/Purite的泪液产品处理的细胞活力。
含有HP-瓜尔胶、PEG 400和丙二醇的泪液产品满足了合适的人工泪液制剂的几个临床前标准。它能为完整的角膜以及培养中的上皮细胞提供长期的干燥保护,并且对细胞没有明显的有害影响。它还提供了受损角膜上皮能够恢复正常屏障功能的条件。制剂中的成分组合似乎提供了一种有效的拟黏液人工泪液产品。这些临床前数据表明该产品将有效地为干眼症患者提供更好的缓解。